SLC5A2 and kidney disorder: Given the well-established beneficial effects of gliflozins on the kidney and heart and promising results of Klotho delivery particularly in kidney disease in conjunction with association studies showing better outcome with higher Klotho levels in renal and cardiovascular diseases, our study sheds new light on the relationship between SGLT2 inhibitors and αKlotho levels (46).